CSBio CSBio

X
[{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-\u03b2 Agonist ASC41 for NASH","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascletis Pharma"},{"orgOrder":0,"company":"Gmax Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gmax's GMA106, Second Generation Obesity\/T2DM\/NASH mAb Gives First in Human Dose","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Gmax Biopharm"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Sciwind"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an Oral Small Molecule GLP-1 Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sciwind"},{"orgOrder":0,"company":"MindRank","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"MindRank"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval from NMPA","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Zhejiang Doer Biologics"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$2,010.0 million","upfrontCash":"$185.0 million","newsHeadline":"Eccogene Enters Exclusive License Agreement with AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Eccogene"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            AstraZeneca will receive an exclusive license to develop and commercialize ECC5004, a small molecule GLP-1 receptor agonist, for the potential treatment of obesity, type-2 diabetes and other comorbidities, in all territories except China.

            Lead Product(s): ECC5004

            Therapeutic Area: Nutrition and Weight Loss Product Name: ECC5004

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: $2,010.0 million Upfront Cash: $185.0 million

            Deal Type: Licensing Agreement November 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonizing GLP-1R, glucagon receptor GCGR, and FGF21R, which is investigated for the treatment of obesity and hypertriglyceridemia in New Zealand.

            Lead Product(s): DR10624

            Therapeutic Area: Nutrition and Weight Loss Product Name: DR10624

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 01, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            MDR-001 is a novel, beta-arrestin 2 selective, orally bioavailable small-molecule GLP-1 RA discovered using MindRank's proprietary AI platform, Molecule Pro, for the treatment of obesity and type 2 diabetes mellitus (T2DM).

            Lead Product(s): MDR-001

            Therapeutic Area: Nutrition and Weight Loss Product Name: MDR-001

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            XW014, a novel oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist in development for the treatment of obesity and type 2 diabetes. XW014 is easier to manufacture than GLP-1 peptide drugs and readily bioavailable after oral dosing.

            Lead Product(s): XW014

            Therapeutic Area: Nutrition and Weight Loss Product Name: XW014

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            XW004 is an oral tablet formulation of Ecnoglutide, a novel long-lasting GLP-1 peptide analogue under development for the treatment of obesity, type 2 diabetes and NASH.

            Lead Product(s): Ecnoglutide

            Therapeutic Area: Nutrition and Weight Loss Product Name: XW004

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 13, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            GMA 106 is second generation monoclonal antibody therapy rationally designed utilizing GMAX’s GPCR and M-Body technologies for the treatment of obesity/T2DM/NASH.

            Lead Product(s): GMA106

            Therapeutic Area: Nutrition and Weight Loss Product Name: GMA106

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 11, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The randomised, double-blind, placebo-controlled clinical study enrolled 20 overweight and obese participants with LDL-C greater than 110mg/dL. They were given ASC41 10mg oral tablets or a placebo once daily.

            Lead Product(s): ASC41

            Therapeutic Area: Nutrition and Weight Loss Product Name: ASC41

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 25, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY